Crimson Publishers Publish With Us Reprints e-Books Video articles

Full Text

Cohesive Journal of Microbiology & Infectious Disease

Comments of Clinical and Microbiological Experience with Daptomycin in Chronic Osteomyelitis Treatment

Marcano-Lozada Marcel1,2*

1 Angios Vascular Center & Wound Clinic, Venezuela

2 JM Vargas School of Medicine, Universidad Central de Venezuela, Venezuela

*Corresponding author:Marcel Marcano-Lozada, MD, Microbiology Department, Medical Doctor, Medical Microbiology Specialist, Medical Microbiology Unit, Angios Vascular Center & Wound Clinic, “J.M. Vargas” School of Medicine, Universidad Central de Venezuela, Caracas, Venezuela

Submission: May 25, 2018; Published: October 24, 2018

DOI: 10.31031/CJMI.2018.02.000535

ISSN 2578-0190
Volume2 Issue2


In the last decade, the use of daptomycin (alone or in combination) for the treatment of Chronic Osteomyelitis (CO) due to Staphylococcus aureus shows successful outcomes in the most complicated patients, and emerges as an option to be consider for elderly patients with several associated comorbidities.

The consideration for select daptomycin, a cyclic lipopeptide antibiotic drug, approved for complicated skin and soft tissue infections, right-sided infective endocarditis and bacteraemia due to Staphylococcus aureus [1], but not approved for use in bone infection; to treat a complex pathology like CO, comes from differents factors like daptomycin’s bactericidal activity against Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE), a novel mechanism of action that kills Grampositive bacteria by the disruption of multiple bacterial plasma membrane functions, without penetrating the cytoplasm [2]. Insertion of the lipophilic daptomycin tail into the bacterial cell membrane with oligomerization and channel formation causes rapid membrane depolarization and a potassium ion efflux. Arrest of DNA & RNA synthesis, toxin production, and protein synthesis follows, resulting in bacterial death without lysis of the cell wall, which gives a further advantage in diseases where inflammatory response associated counter antimicrobial use producing cell lysis [3-5], in addition, the in vitro potency of daptomycin has been demonstrated against Vancomycin resistant S. aureus (VRSA) and methicillin-resistant coagulase-negative staphylococci (MRCNS). The synergic effect for daptomycin that has been described in vitro with aminoglycosides (gentamicin), oxacillin, other betalactamics, macrolides and rifampicin, is very valuable to biofilm disease infections treatment, and this antibiofilm activity and reduction of the rifampicin resistance appearance makes a great value. Not antagonism interactions was observed with daptomycin use in combination with several antimicrobial agents, only additive, synergistic effect or indifference were reported. Another relevant aspect is the partial anti-biofilm activity of daptomycin, combined or alone.

Daptomycin exhibits a dose-dependent post-antibiotic effect lasting from 1 to 6 hours against E. faecalis and S. aureus after exposure to concentrations ranging from 0.25 to 16mg/L (i.e., between one- and eightfold the MIC) [2,6-8]. Its 8-hours half-life, results in once-daily dosing gives a linear pharmacokinetics at doses up to 12mg/kg, with minimal drug accumulation.

Daptomycin distributes primarily in the plasma, with penetration to vascularized tissues. The drug is highly protein-bound (92%); excretion occurs primarily via the kidneys. Approximately 80% of the total dose, of which two-thirds is intact drug, is recovered in the urine. In patients with severe renal impairment (creatinine clearance < 30mL/min), the dosing interval is increased from once daily to every 48 hours. Daptomycin’s unique mechanism of action and its lack of metabolization by cytochrome p450 or other hepatic enzymes results in an absence of drug-drug interactions.

The most frequent side effect with daptomycin use is myopathy, but this mild myopathy was easily predicted and monitored by measuring serum creatine phosphokinase (CPK) concentration, and in the majority of cases, it was reversible upon the cessation of therapy [9]. Activity of daptomycin in bone infection were documented in real-life experience of several authors in retrospective studies [10-13], with clinical success and microbiological eradication of the bacteria. Another reasons to choose daptomycin (without approval for use in bone infection) is the nature of our patients, elderly people (65 or more years old), with huge comorbidities as high blood pressure (HBP), diabetes mellitus (DM), peripheral arterial occlusive disease and/ or chronic venous insufficiency, liver and/or kidney function impairment, the need of a prolonged treatment (6 or more weeks) using intravenous path without hospital admission (daptomycin regimens can be used as Outpatient Parenteral Antimicrobial Therapy -OPAT-), and considering the prior antimicrobial therapy (many patients previously received 3 or even 4 kinds of regimens without satisfactory outcomes), in the main of circumstances due to toxicity, microorganism resistance to antimicrobial drugs, biofilm-producer strains, poor bactericidal activity of the drug into the bone, low drug concentration in bone tissue, short time of treatment or failure in the switch among attack-phase drugs and consolidation-phase drugs.

Our experience working in a multidisciplinary healthcare group, where clinicians, surgeons, microbiology & clinical laboratory professionals interact day-by-day at the bedside (or next to the outpatient treatment room) of the patient, promotes more efficients outcomes. Our “know how” based on many years of management of very severe & complicated cases, and the concept of limb-salvation over the classical point-of-view of limb-amputation, increases our patients quality of life and gaves us the possibility to give some advices or recommendations in order to improve management of bone infections.

One of the most complicated cases of chronic osteomyelitis is when the patient comes to the clinic after years of differents treatments without a complete resolution of its problem, at this point, the “collateral damage” produced by the antimicrobial treatments, lead the selection of a multi-drug resistant microorganism, in many cases a biofilm-producer strain, in a bone with several architectural damage, in a patient with limitations to use some kind of therapeutic regimens (liver disease, kidney failure, concomitant treatments for cardiovascular and/or metabolic pathologies, and a long etcetera ), rides us to try new options to improve the action of the antimicrobial drugs, for example, reduction of biofilm biomass & elimination of the devitalized bone, all with the surgeons help using new technology like the hydro scalpel, that not cause inflammation; metabolic control of hyperglicemia; increasing the blood flow using red globules morphology modificators & anti-thrombotic agents, all of these with the final outcome of improve life quality of the patient and achieve the cure.

Our experience since 2009, with regimens contain daptomycin as main drug in the attack-phase of treatment of chronic osteomyelitis with curative intention, gave us great results, with a very few limitated adverse events, even in patients whom received extremely-high doses (major than 10mg/Kg/IV/OD), for 4 to 6 weeks, and then was switched to oral agents for consolidation phase for 4 to 6 weeks [14]. The use of daptomycin as monotherapy is controversial, we don’t recommended, but in some special and very particular cases, it was the only option against limb amputation [15]. The most efective combination of daptomycin at high dose is with rifampin (standard dose), reserved to biofilm-producer bacteria, for a time of 6 to 8 weeks, follow by a consolidation phase of 4 to 6 weeks of linezolid at standard dose plus a macrolide (azithromycin or clarithromycin) at standard dose, or a quinolone (moxi or levofloxacin) plus a macrolide [16]. The close monitoring of evolution is the key for the clinical & microbiological successful outcome of the patient, it includes laboratory controls to check acute phase reactants variation (twice a week), radiological control (every 4 or 6 weeks) to ensure the stabilization of lesions and watch the apparition of new lesions , clinical control (once a week) and microbiological control when is possible (bone biopsy), with emphasis in cases with poor evolution.

In our clinical & microbiological experience, daptomycin has an excellent efficacy and safety profile, plus great pharmacokinetics & pharmacodynamics characteristics for use in OPAT, even for prolonged periods, in elderly patients with multiple comorbidities in order to eradicate bacteria (even biofilm-producers) and cure chronic osteomyelitis.


  1. Novartis Europharm Ltd. (2009) Cubicin (daptomycin) Summary of Product Characteristics.
  2. Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR (1992) Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 36: 318-325.
  3. Tedesco KL, Rybak MJ (2004) Daptomycin. Pharmacotherapy 24: 41-57.
  4. Silverman JA, Oliver N, Andrew T, Li T (2001) Resistance studies with daptomycin. Antimicrob Agents Chemother 45(6): 1799-1802.
  5. Ammerlaan HS, Bonten MJ (2006) Daptomycin: graduation day. Clin Microbiol Infect 12(suppl 8): 22-28.
  6. Credito K, Lin G, Appelbaum PC (2007) Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother 51: 1504-1507.
  7. Rand KH, Houck HJ (2004) Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48: 2871-2875.
  8. Tally FP, De Bruin MF (2000) Development of daptomycin for Grampositive infections. J Antimicrob Chemother 46: 523-526.
  9. Tally FP, Zeckel M, Wasilewski MM, Carini C, Berman CL, et al. (1999) Daptomycin: a novel agent for Grampositive infections. Expert Opin Investig Drugs 8(8): 1223-1238.
  10. Gonzalez-Ruiz A, Gargalianos-Kakolyris P, Timerman A, Sarma J, Jose Gonzalez Ramallo V, et al. (2015) Daptomycin in the clinical setting: 8-Year Experience with gram-positive bacterial infections from the EUCORE( SM) Registry. Adv Ther 32(6): 496-509.
  11. Ramallo VJG, Allen M, Seaton RA, Marcano-Lozada M, Prisco V, Gonzalez- Ruiz A, et al. (2012) Results from a noninterventional study: daptomycin is effective as outpatient parenteral antibiotic therapy. Poster 1845, Program and abstracts of the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31-April 03 2012. London, UK.
  12. Seaton RA, Gonzalez-Ramallo VA, Prisco V, Marcano-Lozada M, Gonzalez- Ruiz A, et al. (2013) Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience. Int J Antimicrob Agents 41(5): 468-472.
  13. Lamp KC, Friedrich LV, Mendez-Vigo L Russo R (2007) Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 120 Suppl 1: S13-S20.
  14. Marcano-Lozada M, Molero-Leon S (2018) Dawn of the biofilm disease: Highlights about biofilm in bone and joint & prosthetic joint infections pathogenesis, diagnosis and treatment. J Microbiol Modern Tech 3(1): 104.
  15. Marcano-Lozada M, Molero-Leon S (2017) Biofilm-producer MRSA chronic osteomyelitis in a diabetic patient successfully treated with antimicrobial monotherapy. J Exp Microbiol 4(3): 00108.
  16. Marcano-Lozada Marcel, Silvia Leon Molero (2016) Highlights of antimicrobial use in osteomyelitis as prototype of disease biofilms in Venezuela. J Exp Microbiol 3(4): 00096.

© 2018 Marcano-Lozada Marcel. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.